Xconomy | Seattle - Business + Technology in the Exponential Economy

Accelerator’s New Startup, Xori, Aims to Use Chicken Cells to Make Better Antibody Drugs
Ramgen Power Gets $20M, Best Buy Backs Dashwire, WildTangent Teams Up With Mochi, & More Seattle-Area Deals News
OVP Leads $15M Series C Round for Limerick BioPharma
Dendreon’s Manufacturing Challenge, Archus Cuts Deep, Accelerator Company Launches & More Seattle-Area Life Sciences News
Washington Venture Investing Gravitates to Biotech—The Regional Top 10 List

Xori Gets $2.1M From Accelerator

The latest biotech startup from Seattle-based Accelerator, Xori, has received $2.1 million out of a $4.5 million financing round, according to a regulatory filing. The company (pronounced Chore-ee) is testing technology from the lab of Nancy Maizels at the University of Washington, which seeks to develop antibody drugs through a new technique in genetically modified chicken cells, as I described in this feature story yesterday.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: